光自己組み立て金属サイクルを組み込むユニークなポリマーの抗腫瘍活性
Guocan Yu1, Mingming Zhang2, Manik Lal Saha2
1Laboratory of Molecular Imaging and Nanomedicine, National Institute of Biomedical Imaging and Bioengineering, National Institutes of Health , Bethesda, Maryland 20892, United States.
Journal of the American Chemical Society
|October 12, 2017
まとめ
この研究は,がん治療のための新しいプラチナベースの超分子調整複合体を導入します. これらの自己組織化ナノ粒子は 強力な抗腫瘍活性と 薬剤の放出制御を示し 癌治療の有望な新しいアプローチを提供します
科学分野:
- 超分子化学
- 材料科学
- ナノテクノロジー
- 癌 生物学
背景:
- プラチナベースの複合体は抗がん作用があることが知られていますが,その超分子調整複合体は十分に研究されていません.
- 新薬投与システムの開発は 癌治療の有効性を向上させ 副作用を減らすために不可欠です
研究 の 目的:
- ナノ粒子に自己組み立てられる新しいプラチナ含有アンフィフィリックコポリマーを合成し,特徴づけること.
- ナノ粒子の形状と大きさの細胞吸収と細胞毒性への影響を調査する.
- これらのナノ粒子からプラチナ製薬とドクソルビシン (DOX) を併用した抗癌効果を評価する.
主な方法:
- プラチナ製の抗がん剤 (PhenPt) と集積誘発放射性プローブを組み込んだ四腕アンフィフィリックコポリマー (Pt-PAZMB-b-POEGMA) の合成.
- コポリマーをナノ粒子と小胞に自己組み立て
- 細胞の吸収,内細胞経路,細胞毒性を評価するインビトロ試験.
- ドクソルビシン (DOX) の封じ込めと,制御された薬物放出メカニズムの調査.
- 抗腫瘍性能と全身性毒性のインビボ評価
主要な成果:
- コポリマーがナノ粒子に自己組み立て (約. 50 nm) と小胞である.
- ナノ粒子のサイズと形態は 細胞の吸収経路,速度,内部化量に影響を与えました
- DOXを搭載したナノ粒子は 抗がん効果を示した
- グルタチオンの誘発による制御された薬剤の放出が達成された.
- DOXを搭載したナノ粒子は,EPR効果による低全身毒性で,著しい抗腫瘍効果を示した.
結論:
- 新しいプラチナ基の超分子組は 癌治療のために効果的に設計できます
- セルフアセンブリされたナノ粒子は プラチナ製薬とDOXのような化学療法薬の 共同投与のための多用途のプラットフォームを提供します
- これらのシステムは,増強された抗腫瘍性能と減少した全身的毒性を有望に示し,臨床翻訳のためのさらなる調査を正当化しています.
関連する概念動画
02:07Tumor Progression
Tumor progression is a phenomenon where the pre-formed tumor acquires successive mutations to become clinically more aggressive and malignant. In the 1950s, Foulds first described the stepwise progression of cancer cells through successive stages.
Colon cancer is one of the best-documented examples of tumor progression. Early mutation in the APC gene in colon cells causes a small growth on the colon wall called a polyp. With time, this polyp grows into a benign, pre-cancerous tumor. Further...
Colon cancer is one of the best-documented examples of tumor progression. Early mutation in the APC gene in colon cells causes a small growth on the colon wall called a polyp. With time, this polyp grows into a benign, pre-cancerous tumor. Further...
02:53Adaptive Mechanisms in Cancer Cells
Cancer cells accumulate genetic changes at an abnormally rapid rate due to the defects in the DNA repair mechanisms. From an evolutionary perspective, such genetic instability is advantageous for cancer development. Mutant cell lines accumulate a series of beneficial mutations that contribute to their progression into cancer.
Some of the advantages that cancer cells have on normal cells include - enhanced ability to divide without terminally differentiating, induce new blood vessel formation,...
Some of the advantages that cancer cells have on normal cells include - enhanced ability to divide without terminally differentiating, induce new blood vessel formation,...
02:30Metastasis
Metastasis is the spread of cancer cells from the original site to distant locations in the body. Cancer cells can spread via blood vessels (hematogenous) as well as lymph vessels in the body.
Epithelial-to-Mesenchymal Transition
The epithelial-to-mesenchymal transition or EMT is a developmental process commonly observed in wound healing, embryogenesis, and cancer metastasis. EMT is induced by transforming growth factor-beta (TGF-β) or receptor tyrosine kinase (RTK) ligands, which further...
Epithelial-to-Mesenchymal Transition
The epithelial-to-mesenchymal transition or EMT is a developmental process commonly observed in wound healing, embryogenesis, and cancer metastasis. EMT is induced by transforming growth factor-beta (TGF-β) or receptor tyrosine kinase (RTK) ligands, which further...
02:49Cancer Therapies
Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
02:56Treatment Resistant Cancers
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
01:27Tumor Immunotherapy
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.